Eyepoint Pharmaceuticals (NASDAQ:EYPT) announced its quarterly earnings results on Thursday. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.01), Fidelity Earnings reports. Eyepoint Pharmaceuticals had a negative net margin of 621.04% and a negative return on equity of 165.24%. The company had revenue of $2.51 million for the quarter, compared to analyst estimates of $4.81 million.
EYPT stock traded down $0.21 during midday trading on Friday, hitting $1.45. 1,551,100 shares of the company traded hands, compared to its average volume of 422,976. The stock has a market capitalization of $247.67 million, a price-to-earnings ratio of -2.50 and a beta of 1.79. The business has a 50 day simple moving average of $2.12 and a 200-day simple moving average of $1.71. Eyepoint Pharmaceuticals has a twelve month low of $1.19 and a twelve month high of $2.82. The company has a quick ratio of 5.31, a current ratio of 5.46 and a debt-to-equity ratio of 1.75.
Several brokerages have commented on EYPT. Laidlaw began coverage on Eyepoint Pharmaceuticals in a report on Monday, November 4th. They set a “buy” rating and a $5.00 price target on the stock. B. Riley lowered their price target on Eyepoint Pharmaceuticals from $5.75 to $4.00 and set a “buy” rating on the stock in a report on Tuesday, September 24th. ValuEngine downgraded Eyepoint Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday. Guggenheim began coverage on Eyepoint Pharmaceuticals in a report on Thursday, September 12th. They set a “buy” rating and a $4.00 price target on the stock. Finally, Zacks Investment Research upgraded Eyepoint Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Eyepoint Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $3.95.
EyePoint Pharmaceuticals, Inc, a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States and Europe. It provides ILUVIEN for the treatment of diabetic macular edema; YUTIQ, a non-erodible fluocinolone acetonide insert for the treatment of non-infectious posterior uveitis (NIPU) that is in the Phase III clinical trials; and Retisert (fluocinolone acetonide intravitreal implant), a sustained-release implant for the treatment of posterior segment uveitis.
Featured Story: What is an economic bubble?
Receive News & Ratings for Eyepoint Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyepoint Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.